Biopharmconsortium Blog

Expert commentary from Haberman Associates biotechnology and pharmaceutical consulting.

Posts filed under: About Our Blog

Our new website, and continuing R&D on antibody drugs for cancer immunotherapy

TweetHaberman Associates has a new website, with the same URL as previously but with many improvements. This article is the first Biopharmconsortium Blog post to be posted after the new website has gone online. Please explore the new site, and send any comments on the site to us. In addition to announcing our new website,…

Agios Pharmaceuticals continues to progress

TweetBecause of being very busy with other projects, we have not posted an article on this blog since April 10, 2014. However, the Biopharmconsortium Blog is still here. More importantly, Haberman Associates biotech/pharma consulting is still here, and we’re still accepting new clients. Thanks to the many readers who have continued to follow our website…

Breakthrough of the year 2013–Cancer Immunotherapy

TweetAs it does every year, Science published its “Breakthrough of the Year” for 2013 in the 20 December 2013 issue of the journal. Science chose cancer immunotherapy as its Breakthrough of the Year 2013. In its 20 December 2013 issue, Science published an editorial by its Editor-in-Chief, Marcia McNutt, Ph.D., entitled “Cancer Immunotherapy”. The same…

Bluebird Bio, Celgene, and Adoptive Immunotherapy for Cancer

TweetThe Biopharmconsortium Blog includes several articles that are–in whole or in part–about adoptive T-cell immunotherapy [or adoptive cell transfer (ACT)] for cancer. In particular, we have produced two blog articles that discuss the Novartis/University of Pennsylvania (Penn) collaboration, which is aimed at finally commercializing adoptive immunotherapy for cancer. “Is Novartis Building A Viable Business Model…

Haberman Associates has a new website!

Tweet Haberman Associates now has a new website, which is available at http://biopharmconsortium.com. Our new site has an attractive, up-to-date look and feel, and also contains updated news and other updated content. We have also fully integrated our Biopharmconsortium Blog into our new site. Our blog resides at http://biopharmconsortium.com/blog. There has been a hiatus in…

What is Haberman Associates?

Tweet A few weeks ago, I attended a presentation that was produced by another consulting firm, which we shall call Company X. They began their presentation with a discussion of “what is Company X?” Then they went on the the substance of their presentation. In the same vein, as the producers of the Biopharmconsortium Blog,…

The Biopharmconsortium Blog hiatus to end soon!

Tweet  As you all may have noticed, we have not had a post on the Biopharmconsortium Blog during the entire month of February, 2012. This unintended hiatus happened because of the need to finish up other work. We’re almost finished with these projects, and have several ideas for blog articles (including some articles that we…

Read the cancer immunotherapy review in the 22 December 2011 issue of Nature!

Tweet  We commend for your New Year’s reading the review article entitled “Cancer immunotherapy comes of age” in the 22 December 2011 issue of Nature. It was written by Drs. Ira Mellman (Genentech),  George Coukos (University of Pennsylvania School of Medicine), and Glenn Dranoff (Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Center/Brigham…

A ray of hope–The Scientist magazine saved from the brink of extinction!

Tweet  I hope that many of you have the special October 2011 issue of The Scientist, celebrating the publication’s 25th anniversary, in your hands. That issue is full of articles by leading researchers, including George Church, E.O. Wilson, Craig Venter, Mary-Claire King, Stephen Friend, and many others. The Scientist is one of my favorite publications….

For the people of Japan

TweetOn March 3, 2011, we posted an article on this blog on the acquisition of Plexxikon by Daiichi Sankyo. Then on March 11, 2001, came the 9.0-magnitude Tōhoku earthquake, followed by the devastating tsunami, with the loss of thousands of lives, and extensive damage to the infrastructure of Japan. Particularly troubling is the damage to…